Clinical trials: Second-Line
Solid Tumor
A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors
This is a multi-center, phase Il trial to evaluate the efficacy and safety of microwave ablation combined with immunotherapy ± anti-angiogenic drugs in the treatment of advanced second-line and above solid tumors.
- Trial name
- NCT06537505
- Testing
- Adebrelimab, Apatinib, microwave ablation
- Volunteers
- 60 people
- Sponsor
- Beidahuang Industry Group General Hospital
Advanced Non-Small Cell Lung Cancer
Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC
The aim of this study is to compare time to progression between the combination pemetrexed-carboplatin and pemetrexed alone in previously treated patients with locally advanced or metastatic NSCLC.
- Trial name
- NCT00786331
- Testing
- Pemetrexed, Pemetrexed plus carboplatin
- Where
- 21 sites in Italy
- Volunteers
- 230 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Non Small Cell Lung Cancer, Oligoprogressive
Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma
This is a randomized phase II study designed to evaluate the effect of local consolidative radiation therapy (LCT) to all sites of oligoprogressive disease in patients with metastatic non-small cell lung carcinoma who have…
- Trial name
- NCT04485026
- Testing
- Local consolidative radiation therapy, Standard of care radiation therapy
- Sponsor
- Wake Forest University Health Sciences
Hepatocellulcar Carcinoma
Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment
There is no definitive evidence regarding the therapeutic efficacy of PD-1 inhibitors combined with tyrosine kinase inhibitors (TKIs) after disease progression following first-line treatment with bevacizumab plus sintilimab for…
- Trial name
- NCT07537985
- Testing
- Lenvatinib, Regorafenib, PD-1 Inhibitor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
NSCLC
Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer
Data regarding nivolumab as second line treatment in advanced non-small cell lung cancer (NSCLC) are based on selected populations and might not reflect daily practice.
- Trial name
- IMMUNOBZH (NCT04858204)
- Where
- 7 sites in France
- Volunteers
- 259 people
- Sponsor
- University Hospital, Brest
FGFR1 Gene Amplification, FGFR1 Gene Mutation
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
This phase II/III trial studies how well FGFR inhibitor AZD4547 (AZD4547) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment.
- Conditions
- FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation
- Trial name
- NCT02965378
- Testing
- Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis
- Where
- 1,084 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
In this single-arm, phase II study, we aimed to evaluate the efficacy and safety of sac-TMT plus bevacizumab in patients with advanced non-squamous NSCLC who showed disease progression on or after first-line ICI plus…
- Trial name
- NCT07244926
- Testing
- Sacituzumab tirumotecan plus bevacizumab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cirrhosis
Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis
Bacterial infections are a frequent complication in liver cirrhosis with a bad prognosis. However, the clinical outcome of cirrhotic patients with serious infections is significantly improved over the last 30 years due to early…
- Trial name
- NCT01820026
- Testing
- Imipenem, Vancomycin, azithromycin
- Where
- Italy
- Volunteers
- 96 people
- Sponsor
- University of Roma La Sapienza
Cholangiocarcinoma
A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma
Primary objective: To investigate the objective response rate in patients with ROS1 or ALK over-expressed locally advanced, or metastatic intrahepatic or hilar cholangiocarcinoma receiving LDK378 Secondary objectives:The…
- Trial name
- NCT02374489
- Testing
- LDK378
- Where
- 2 sites in Taiwan
- Volunteers
- 9 people
- Sponsor
- National Health Research Institutes, Taiwan
Chronic Myelogenous Leukemia - Chronic Phase
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for…
- Trial name
- ASC4REAL-2 (NCT07091019)
- Testing
- TKIs
- Where
- 17 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Novartis Pharmaceuticals
Helicobacter Infections
Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy
patients who had failed previous H. pylori eradication on standard triple therapy were randomized into two regimens: 1, esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d)…
- Trial name
- NCT01792700
- Testing
- esomeprazole, tripotassium dicitrate bismuthate, metronidazole
- Where
- South Korea
- Volunteers
- 648 people
- Sponsor
- Seoul National University Bundang Hospital
Colorectal Cancer, Colorectal Neoplasms
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
This is a randomized, open-label, dose/schedule optimization study comparing NUC-3373/leucovorin (LV)/irinotecan plus bevacizumab (NUFIRI-bev) to 5-FU/LV/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients…
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic
- Trial name
- NCT05678257
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan
- Where
- 59 sites in United States, France and 4 more
- Volunteers
- 180 people
- Sponsor
- NuCana plc
Advanced Solid Tumor, Locally Advanced Solid Tumor
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2…
- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer
- Trial name
- IL Believe (NCT05081609)
- Testing
- TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug
- Where
- 68 sites in United States, Australia and 8 more
- Volunteers
- 320 people
- Sponsor
- Ascendis Pharma Oncology Division A/S
Inoperable Gastric Cancer
FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer
Patients diagnosis with inoperable gastric cancers are treated with palliative chemotherapy. Palliative chemotherapy had proven to be better overall survivals and quality of life in unresectable advanced gastric cancer.
- Trial name
- NCT03067792
- Testing
- 5-fluorouracil, irinotecan and leucovorin, docetaxel and cisplatin
- Volunteers
- 52 people
- Sponsor
- Yonsei University
Colorectal Cancer
Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
The primary objective of this study is to compare the additive efficacy of SIM versus placebo in combination with leucovorin (folinic acid), irinotecan, and fluorouracil (FOLFIRI) as measured by improvement in progression-free…
- Trial name
- NCT01479465
- Testing
- Simtuzumab, Leucovorin, Irinotecan
- Where
- 109 sites in United States, France and 5 more
- Volunteers
- 266 people
- Sponsor
- Gilead Sciences
Colorectal Cancer
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
This is a multi-center, single-arm study to investigate the efficacy and safety of liposomal irinotecan+5-FU/LV+ bevacizumab as second-line therapy in metastatic colorectal cancer in Chinese population.
- Trial name
- NCT06184698
- Testing
- liposomal irinotecan, 5-FU, LV
- Where
- China
- Volunteers
- 173 people
- Sponsor
- Hebei Medical University Fourth Hospital
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (anti PD-1/CTLA-4) combined with albumin-paclitaxel in the second-line treatment of patients with advanced…
- Trial name
- NCT07139587
- Testing
- Iparomlimab/Tuvonralimab (anti PD-1/CTLA-4) combined with albumin-bound paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Qingxia Li
Colorectal Carcinoma
Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
This study is designed to compare the efficacy and safety of two-weekly RAILIRI regimen with FOLFIRI regimen in the treatment of advanced colorectal cancer patients in the second-line setting.
- Trial name
- NCT02376452
- Testing
- Raltitrexed, Irinotecan, 5-fluorouracil
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Chronic Lymphocytic Leukemia
Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)
Bendamustine demonstrated clinical activity in pre-treated hematological malignancies due to its unique mechanism of action distinct from standard alkylating agents.
- Trial name
- NCT01423032
- Testing
- bendamustine, Fludarabine
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- WiSP Wissenschaftlicher Service Pharma GmbH
Colorectal Cancer
Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as liposome-encapsulated irinotecan hydrochloride PEP02, irinotecan hydrochloride, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either…
- Trial name
- PEPCOL (NCT01375816)
- Testing
- FOLFIRI 1-Bevacizumab, fluorouracil, irinotecan hydrochloride
- Where
- France
- Volunteers
- 55 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.